FIG. 5.
BIT225 results in defects in virion assembly. Day 14 MDM were infected chronically with HIV-1Ba-L and treated with BIT225 at 10 μM or with DMSO prior to being fixed for TEM on day 28. (a and b) Shown are DMSO-treated MDM with HIV-1-like particles (indicated by the arrows) (a) and BIT225-treated MDM with aberrant virus-like particles sequestered within intracellular compartments (b). (c and d) Additionally, the cells were lysed for Western blot analysis to determine gross protein differences between BIT225-treated and untreated MDM in equivalent amounts of total protein (c); equivalency of protein amounts was confirmed by analysis of β-actin expression (d).